Morphocell Technologies Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 44

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $50M

  • Investors
  • 3

Morphocell Technologies General Information

Description

Operator of a regenerative medicine company intended to advance treatments using stem cell-based therapies. The company's cell therapy functions as an allogeneic solution that does not necessitate immunosuppression and can be extracted without lasting effects once liver function is restored through minimally invasive procedures, enabling medical professionals with an effective option for acute and chronic liver failure.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 275 Armand-Frappier Boulevard
  • Laval, Quebec H7V 4A7
  • Canada
+1 (514)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 275 Armand-Frappier Boulevard
  • Laval, Quebec H7V 4A7
  • Canada
+1 (514)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Morphocell Technologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Later Stage VC (Series A) 01-Dec-2025 $50M Completed Pre-Clinical Trials
To view Morphocell Technologies’s complete valuation and funding history, request access »

Morphocell Technologies Patents

Morphocell Technologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-7699644-B2 Process for generating a hepatic lineage cell population from endodermal cells and cell compositions comprising same Active 25-May-2018
JP-2024028866-A Process for making cell populations of hepatic lineage from endodermal cells and cellular compositions comprising same Active 25-May-2018
JP-2025148360-A Process for making cell populations of hepatic lineage from endodermal cells, and cellular compositions comprising the same Pending 25-May-2018
AU-2019273134-A1 Process for making cell populations of the hepatic lineage from endodermal cells and cellular compositions comprising same Active 25-May-2018
AU-2019273134-B2 Process for making cell populations of the hepatic lineage from endodermal cells and cellular compositions comprising same Active 25-May-2018 C12N5/0679
To view Morphocell Technologies’s complete patent history, request access »

Morphocell Technologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Morphocell Technologies Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
CDP Venture Capital (Rome) Venture Capital Minority
Genson Capital Venture Capital Minority
Investissement Quebec PE/Buyout Minority
To view Morphocell Technologies’s complete investors history, request access »

Morphocell Technologies FAQs

  • When was Morphocell Technologies founded?

    Morphocell Technologies was founded in 2018.

  • Where is Morphocell Technologies headquartered?

    Morphocell Technologies is headquartered in Laval, Canada.

  • What is the size of Morphocell Technologies?

    Morphocell Technologies has 44 total employees.

  • What industry is Morphocell Technologies in?

    Morphocell Technologies’s primary industry is Drug Discovery.

  • Is Morphocell Technologies a private or public company?

    Morphocell Technologies is a Private company.

  • What is Morphocell Technologies’s current revenue?

    The current revenue for Morphocell Technologies is .

  • How much funding has Morphocell Technologies raised over time?

    Morphocell Technologies has raised $50M.

  • Who are Morphocell Technologies’s investors?

    CDP Venture Capital (Rome), Genson Capital, and Investissement Quebec have invested in Morphocell Technologies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process